Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
Fabiola AtzeniFrancesco GozzaAgostino RivaAlessandra AlciatiJames B GallowayPublished in: Expert opinion on pharmacotherapy (2023)
The overall data showed a slightly higher risk of HZ in patients treated with bDMARDs, and more pronounced for those treated with JAKi. As management strategies, we suggest an effective vaccination campaign and a focus on early diagnosis.